Markers of kidney tubule function and risk of cardiovascular disease events and mortality in the SPRINT trial.

ABSTRACT:

Aims

Biomarkers of kidney tubule injury, inflammation and fibrosis have been studied extensively and established as risk markers of adverse kidney and cardiovascular disease (CVD) outcomes. However, associations of markers of kidney tubular function with adverse clinical events have not been well studied, especially in persons with chronic kidney disease (CKD).

Methods and results

Using a sample of 2377 persons with CKD at the baseline Systolic Blood Pressure Intervention Trial (SPRINT) visit, we evaluated the association of three urine tubular function markers, alpha-1 microglobulin (α1m), beta-2 microglobulin (β2m), and uromodulin, with a composite CVD endpoint (myocardial infarction, acute coronary syndrome, stroke, acute decompensated heart failure, or death from cardiov

SUBMITTER: Garimella PS 

PROVIDER: S-EPMC6837159 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature